Cadrenal Therapeutics(NASDAQ:CVKD) 
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fib...
Website: https://www.cadrenal.com/
Founded: 2022
IPO Price: $5 (Jan 20, 2023)
Full Time Employees: 1
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 16.19
H 16.91
L 15.38
C 16.17
V 27,800
10EMA 16.17
20EMA 16.17
60EMA 16.17
120EMA 16.17
250EMA 16.17